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A B S T R A C T
In the present study, the synthesis and cytotoxic eﬀect of six stilbenes and three oxepine derivatives against two
cancerous – HeLa and U87, and two normal – EUFA30 and HEK293 cell lines has been reported. The results of
cytotoxic assay and ﬂow cytometry analysis revealed that compounds 9-nitrobenzo[b]naphtho[1,2-f]oxepine
(4), (E)-3,3′,4,4′,5,5′-hexamethoxystilbene (6) and 4-hydroxy-2′,4′-dinitrostilbene (8) were the most active and
their interaction with tubulin (crystal structure from PDB) has been analyzed by computer molecular modeling.
Molecular docking of these compounds on colchicine binding site of the tubulin indicates the interaction of (4),
(6) and (8) with tubulin. The compound (4) could interact stronger with tubulin, relative to colchicine, however,
with no selectivity of action against cancer and normal cells. Conversely, compounds (6) and (8) interact more
weakly with tubulin, relative to colchicine but they act more selectively towards cancerous versus normal cell
lines. Obtained results proved that the compounds that are the most active against cancerous cells operate
through tubulin binding.
1. Introduction
Microtubules display various functions in living cells. They form a
cytoskeleton, allow intracellular transport, mobility, and also build a
mitotic spindle to provide ﬂexibility to the cell that is necessary to di-
vide. In all eukaryotic cells, two globular proteins – α- and β-tubulin
each about 50 kDa are present. These two molecules form an αβ-tubulin
heterodimer with two guanosine triphosphate (GTP) molecules. In
certain conditions, these heterodimers attach one to another in a head-
to-tail manner and form protein ﬁber called protoﬁlament. Self-as-
sembly of protoﬁlaments results in the pipe-like structure, known as
microtubule (Fig. 1).
In cells, microtubules are regulated mainly by their polymerization
dynamics which is a reversible process with α- and β-tubulin hetero-
dimers noncovalently added to both ends of microtubule [1]. The
polymerization process is extremely ﬂuid, with tubulin dimers added at
one end, while dimers are removed from the other end. The transition
between these two processes is known as dynamic instability. In vitro,
tubulin polymerizes at a higher rate at the “plus end”, which ends with
the β-subunit. The second end, called “minus end” is terminated with
the α-subunit and polymerizes at slower motion [2].
The microtubule network presented during interphase is dis-
assembled at the beginning of mitosis and replaced by a new network of
spindle microtubules which are four to 100-fold more dynamic than the
microtubule array in the interphase cytoskeleton [3]. If the microtubule
dynamic is disrupted, the cell cycle is arrested in the mitosis phase on
the interface between metaphase and anaphase leading to cell death. In
the tubulin heterodimer structure, we can distinguish at least three
characteristic drug binding sites that inhibit the microtubule activity.
Those are: vinca alkaloids binding site (vinblastine binding site) located
in the proximity of GTP binding site at β-tubulin subunit, paclitaxel
binding site situated at interﬁlament region of β-tubulin and colchicine
binding site ﬁrst described in 2004 by Ravelli et al. located at the in-
terface between α- and β-tubulin heterodimer [4]. Drugs applicable in
clinical oncology occupied only the ﬁrst two of these sites [5]. Micro-
tubule targeting agents (MTA) depending on their structure, bound
with a certain region of tubulin and can interfere with microtubule
dynamics in two diﬀerent manners. The ﬁrst group consists of the mi-
crotubule-stabilizing agent. These include compounds that bind to the
paclitaxel domain: taxanes, epothilones, and discodermolide. The
second group – microtubule-destabilizing agents includes many vinca
alkaloids and compounds that bind to the colchicine domain. Both
microtubule-stabilizing and destabilizing agents inﬂuence the dynamics
and stability of the microtubules even in low concentrations [6]. Im-
paired microtubule activity causes abnormalities in the functioning of
cells functions. Due to the fact that cancer cells are characterized by
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more frequent divisions in comparison to normal cells, they are also
more sensitive to substances that interfere with this process [6].
Therefore, compounds that are inhibitors of microtubule activity are
treated as potential drugs that may be eﬀective in treating cancer. Over
past decades, extensive studies towards compounds interacting with the
colchicine binding site have been conducted [7–11]. However, no mi-
crotubule inhibitor has been found clinically applicable. Colchicine
(Fig. 2) has been found as the ﬁrst drug binding tubulin very tightly,
nevertheless its use in the clinical cancer treatment has been hampered
due to its severe toxicity to normal tissues [12].
Stilbenoids are naturally present in plants and make an important
contribution to biochemical and physiological processes acting also as
natural protective agents to defend the plant against viral and microbial
attack, excessive UV exposure, and diseases. In human, they have been
used as drugs and antitumor agents. Nowdays, combretastatins are
perceived as the most promising microtubule targeting agents binding
the colchicine binding site [13]. Combretastatins CA-1 and CA-4 be-
longing to naturally occurring stilbene derivatives are new vascular
targeting and vascular disrupting agents (Fig. 2) [14]. They possess
outstanding properties to inhibit gastric tumor metastasis and to in-
crease antitumor immune reactivity [15]. CA-1P is the sodium dipho-
sphate prodrug derived
from combretastatin A1, initially isolated form African plant
Combretum caﬀrum, exhibiting remarkable antineoplastic and vascular-
disrupting activities [16,17]. In vivo, combretastatin A1 diphosphate
(CA-1P) is enzymatically dephosphorylated to the active form of com-
bretastatin A1 (CA-1) which causes microtubule depolymerization,
endothelial cell mitotic arrest, and apoptosis [18]. The disodium
phosphate salt of CA-4 (Fosbretabulin) is under phase II/III of a clinical
trial, additionally combined with other anticancer drugs [19]. It is also
worth noticing that the other stilbene compounds have been shown to
possess potent anticancer, anti-inﬂammatory, and antioxidant activities
[20]. The high mortality of cancer patients results from too late or in-
adequate diagnosis of the disease itself and still inadequately eﬀective
therapy. Chemotherapy is one of the most common methods of treat-
ment, however, despite the use of cytostatic, further growth of cancer
cells is still observed. This is mainly due to the creation of multidrug
resistance (MDR) mechanisms. Microtubule binding drugs lead, among
others, to primary resistance being a result of the character of tissue the
tumor originated. This is achieved by changes in the expression of the
MDR repressive gene. The second type is acquired resistance, which
arises in cells originally sensitive to chemotherapy. The most common
cause of resistance is overexpression of the MDR1 gene encoding P-
glycoprotein (Pgp), lowering the intracellular concentration of the drug
and its cytotoxicity. That leads to arising the population of mutant cells
with increased expression of Pgp, thus the drugs act only on the po-
pulation of sensitive cells. P-glycoprotein is a member of a vast family
of structurally similar proteins found in all groups of organisms from
prokaryotes to Homo sapiens. This family is known as ABC carriers
(ATP-binding cassette transporter) binding a broad range of com-
pounds. Adenosine triphosphate (ATP) is also bounded to ABC carriers
and energy form its hydrolysis is utilized for translocation of the
bounded drug to extracellular space [21]. All compounds applicable in
clinical oncology (e.g. vinblastine, taxol, vincristine) target vinca al-
kaloids or taxanes binding sites of tubulin. Despite their high potency,
clinical usage is still limited mainly because of following reasons:
1) In many cases, there is a high probability of developing multi-drug
resistance.
2) Their high lipophilicity enforces usage of surfactants (e.g. Tween
80). This may lead to hypersensitivity of some patients.
3) Due to low solubility in water their administration is restricted to
intravenous injection.
These adverse eﬀects can be largely overcome by the use of com-
pounds that bind to the colchicine binding site, for example, many of
them possess high solubility in water, and hence they can be admini-
strated orally. Moreover, there is no need to use additives improving
solubility, thus there is no risk of hypersensitive reactions. The most
important, they do not lead to the incurred resistance to CA4P, thus not
inﬂuencing its clinical eﬃcacy [22]. In addition, beyond overexpression
of ABC carriers, the causes of drug resistance are tubulin mutations,
occuring after the use of paclitaxel or vinorelbine. Tubulin mutations
and changes in the expression of individual isotypes can induce drug
resistance, either directly by reducing the aﬃnity of drugs to tubulin, or
indirectly through changes in the dynamics of microtubules [23]. Drugs
that bind the colchicine domain, e.g. colchicine or stilbenoids do not
aﬀect the expression of β-tubulin [24].
Continuing our study concerning the synthesis and search for bio-
logically active stilbenes, [25–27] we have directed our attention also
to the dibenzo[b,f]oxepines. These compounds have (Z)- stilbene motif
in their skeletons, and additionally, their aromatic rings are connected
by oxygen. Moreover, dibenzo[b,f]oxepine is an important scaﬀold in
medicinal chemistry and its derivatives occur in several medicinally
important plants [28–32]. We investigated also hydroxy and methoxy
derivative of E-stilbenes, because there are known compounds e.g. re-
sveratrol (RES, (E)-3,5,4′-trihydroksystilben) having medical eﬀects.
Resveratrol is a polyphenol produced by plant species and has been
widely studied due to its ability to inhibit the growth of cancer cells
[33]. Another active stilbene is pterostilbene (4-[(E)-2-(3,5-dimethox-
yphenyl)ethenyl]phenol) which exhibits lipid and glucose-lowering
eﬀects used in the treatment of resistant hematology malignancies. I
also has antioxidant capacity and demonstrates concentration-depen-
dent anticancer activity [34–37]. There are only few data regarding
their activity as microtubule targeting agents [38].
2. Material and methods
2.1. Chemistry
Substrate (2) are commercially available from Sigma-Aldrich and
Fig. 1. Microtubule structure.
Fig. 2. Structure of colchicine, of combretastatin A-1, of combretastatin A-4 and of dibenzo [b,f]oxepine.
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was protected with an ethyl group according to [39], compounds (1)
and (3) were synthesized according to literature procedures [26] and
[27] respectively. Molecule (6) was prepared according to modiﬁed
literature procedures: [27,33].
2.1.1. Synthesis of (5a) and (6)
To a well-stirred and cooled to 0 °C suspension of zinc powder
(9.40 g, 143.8 mmol) in anhydrous THF (100.0 mL), titanium tetra-
chloride (13.62 g, 7.86mL, 71.8 mmol) was added dropwise. The mix-
ture was stirred at 0 °C for 0.5 h and then p-methoxybenzaldehyde
(59.8 mmol) or solution of 3,4,5-trimethoxybenzaldehyde (59.8 mmol)
in THF (25ml) was slowly added. The suspension was reﬂuxed for 24 h
under argon, then cooled to 0 °C and diluted with cold water (200mL).
Zinc dust and precipitated stilbene were ﬁltered oﬀ, washed with dis-
tilled water (2× 50mL) and methanol (2× 25mL) and dried under
vacuume. After recrystallization and hot ﬁltration, pure stilbene was
obtained.
(E)-4,4′-dimethoxystilbene (5a), Yield 68 %, product was crystal-
lized from toluene/ethyl acetate. 1H NMR (CDCl3, 500MHz): δ 3.83 (s,
6H, CH3O), 6.88–6.91 (m, 4H, Ar), 6.93 (s, 2H, CH=CH), 7.41–7.44
(m, 4H, Ar). 13C NMR (CDCl3, 125MHz): δ 55.5, 114.3, 126.3, 127.6,
130.6, 159.2. FTIR (νmax/ cm−1): 3069, 3017, 2955, 2937, 2911, 2838,
2051, 1987, 1894, 1832, 1606, 1575, 1511, 1464, 1447, 1440, 1425,
1306, 1269, 1244, 1214, 1177, 1152, 1110, 1027, 967, 955, 832, 824,
815, 744, 728, 640. HRMS (ESI): C16H16O2Na+, calcd m/z 263.1048 ;
found m/z 263.1049.
(E)-3,3′,4,4′,5,5′-hexamethoxystilbene (6), Yield 81 %, product was
crystallized from toluene. 1H NMR (CDCl3, 500MHz): δ 3.87 (s, 6H,
CH3O), 3.91 (s, 12H, CH3O), 6.73 (s, 4H, Ar), 6.93 (s, 2H, CH=CH).
13C NMR (CDCl3, 125MHz): δ 56.2, 61.1, 103.6, 128.2, 133.0, 138.0,
153.5. FTIR (νmax/ cm−1): 3006, 2976, 2941, 2833, 1583, 1508, 1464,
1418, 1350, 1316, 1263, 1248, 1231, 1187, 1119, 993, 966, 919, 830,
782, 675, 651. HRMS (ESI): C20H24O6Na+, calcd m/z 383.1471; found
m/z 383.1470.
2.1.2. Synthesis of (5)
was prepared according to literature procedures [27]: 7-methoxy-1,2,3-
tris(4-methoxyphenyl)-1,2,3,4-tetrahydronaphthalene (5). White solid,
yield: 432mg (90 %), m.p. 139−140 °C (EtOH). 1H NMR (500MHz,
CDCl3, 298 K): δ (ppm): the ring: 3.06 (1H, AB spin system, dd 2J =
-16.5 Hz, 3J=4.5 Hz, H4), 3.18 (1H, AB spin system, dd, 3J = 11.5 Hz,
H4′), 4.18 (1H, d, 3J=10.5 Hz, H1), 3.15 (1H, dd, 3J=11Hz, H2), 3.33
(1H, ddd, H3); A ring: 6.75 (2H, d, 3J =8.5 Hz, H2,H6), 6.66 (2H, d,
H3,H5), 3.74 (3H, s, OCH3); B ring 6.68 (2H, d, 3J=8.5 Hz, H2, H6),
6.52 (2H, d, H3, H5), 3.65 (3H, s, OCH3); C ring: 6.98 (2H, d,
3J=8.5 Hz, 1 H2, H6), 6.64 (2H, d, H3, H5), 3.70 (3H, s, OCH3); D
ring 7.07(1H, d, 3J =8.5 Hz, H5), 6.34 (1H, d, 4J = 2.5 Hz, H8), 6.72
(1H, dd, H6), 3.63 (3H, s, OCH3). 13C NMR (125MHz, CDCl3, 298 K): δ
(ppm): the ring: 55.02(C1), 55.53(C2), 46.35(C3), 39.65(C4); A ring:
137.58(C1), 130.19(C2,C6), 113.45(C3,C5), 157.64 (C4), 55.09(OCH3);
B ring: 135.18(C1), 129.26(C2,C6), 113.03 (C3,C5), 157.18(C4) 54.91
(OCH3); C ring: 136.82(C1), 128.52 (C2,C6), 113.33 (C3,C5),
157.45(C4),55.06 (OCH3); D ring 129.37 (C4a), 129.06 (C5), 112.07
(C6), 157.75 (C7), 114.86 (C8), 141.45 (C8a), 55.20(OCH3). HRMS
(ESI): C32H32O4Na+, calcd m/z 503.2198; found m/z 503.2195.
2.1.3. Synthesis of (4, 10)
A mixture of aromatic aldehyde (12mmol) and 2.19 g (12mmol) of
2,4-dinitrotoluene was ground in a mortar and then placed in a thick-
walled glass test tube with a Teﬂon closure and 1.09mL (0.937 g,
11.0 mmol) of piperidine was added. The contents of the vessel were
heated at 90 °C for 2 h under argon, then dissolved in 150mL of ethyl
acetate and washed with 0.25M hydrochloric acid (2× 25mL) and
water to neutral pH. Then, the solvent and the remaining water were
removed in vacuo and the crude product was puriﬁed by crystallization
from methanol or ethanol with the additive of charcoal. After hot ﬁl-
tration, a pure stilbene was obtained.
9-nitrobenzo[b]naphtho[1,2-f]oxepine (4), Yield 29 %, product was
crystallized from methanol, 1H NMR (500MHz, CDCl3): δ 7.04 (d, 1H,
J= 11.5 Hz, CH=), 7.35 (d, 1H, J= 8.5 Hz, Ph-NO2), 7.42 (d, 1H,
J= 9.0 Hz, Napht), 7.48 (ddd, 1H, J= 8.0, J= 7.0, J= 1.5 Hz,
Napht), 7.57 (ddd, 1H, J= 8.0, J= 7.0,J= 1.5 Hz, Napht), 7.64 (d,
1H, J= 11.5 Hz, CH=), 7.83–7.85 (m, 1 H), 7.886 (d, 1H, J= 9.0 Hz,
Napht), 8.00 (dd, 1H, J= 2.5 Hz, J= 8.5 Hz, Ar-NO2), 8.05 (dd, 1H,
J= 8.5 Hz, J= 1.0 Hz), 8.08 (d, 1H, J= 2.5 Hz, Ar-NO2). 13C NMR
(125MHz, CDCl3): δ 117.0, 120.3, 121.1, 123.3, 123.4, 125.7, 127.5,
128.8, 129.2, 129.3, 130.1, 131.5, 131.6, 131.9, 137.9, 148.7, 156.0,
157.7. FTIR (νmax/cm-1) 3101, 3074, 3037, 1615, 1591, 1522, 1483,
1438, 1400, 1341, 1320, 1227, 1207, 1191, 1149, 1129, 1078, 1062,
925, 896, 858, 850, 821, 808, 794, 760, 737, 725, 690, 670, 635. HRMS
(ESI): C18H11NO3Na+,calcd. m/z 312.0637- found 312.0638.
3-ethoxy-4-hydroxy-2′4′-dinitrostilbene (10) Yield 41 %, the pro-
duct was crystallized from ethanol. 1H NMR (500MHz, CDCl3): δ 1.50
(t, 3H, J= 7.0 Hz, CH3), 4.19 (q, 2H, J= 7.0 Hz, CH2O), 5.92 (s, 1H,
OH), 6.95 (d, 1H, J= 8.0 Hz, Ar-3-CH3CH2O-4-OH), 7.07–7.09 (m, 2H,
Ar-3-CH3CH2O-4-OH), 7.23 (d, 1H, J= 16.0 Hz, CH=), 7.45 (d, 1H,
J= 16.0 Hz, CH=), 7.95 (d, 1H, J= 9.0 Hz, Ar-2,4-NO2), 8.38 (ddd,
1H, J= 0.5 Hz, J= 2.5, J= 9.0 Hz, Ar-2,4-NO2), 8.78 (d, 1H,
J= 2.5 Hz, Ar-2,4-NO2). 13C NMR (125MHz, CDCl3): δ 14.9, 64.9,
109.7, 114.9, 118.6, 120.9, 122.8, 127.1, 128.3, 128.5, 138.5, 139.2,
145.9, 146.4, 147.3, 147.9. FTIR (νmax/cm-1) 3493, 3116, 2988, 2944,
2887, 1625, 1601, 1586, 1555, 1513, 1474, 1443, 1432, 1401, 1381,
1342, 1327, 1303, 1291, 1275, 1261, 1238, 1218, 1194, 1170, 1141,
1126, 1061, 1043, 973, 967, 962, 937, 920, 904, 852, 834, 826, 813,
737, 727, 713, 682. HRMS (ESI) : C16H14N2O6Na+, calcd. m/z
353.0749 -found 353.0748.
2.1.4. Synthesis of (7, 8, 9)
To a stirred mixture of 2,4-dinitrotoluene (2.19 g, 12mmol), alde-
hyde (12mmol) and toluene (20ml) under argon, dry piperidine
(1.09 ml, 0.937 g, 11.0mmol) was added. After 3 h of heating at 90 °C,
the solvent was distilled oﬀ on a rotary evaporator. Then ethyl acetate
(150mL) was added to the residue, and the resulting mixture was
washed with 0.5 M hydrochloric acid (2×40mL) and water to neutral
pH. Next, the solvent and the remaining water were removed in vacuo
and the crude product was puriﬁed by crystallization from methanol or
ethanol with the additive of charcoal. After hot ﬁltration, pure stilbene
was obtained.
3-hydroxy-2′,4′-dinitrostilbene (7), Yield 22 %, product was crys-
tallized from ethanol, 1H NMR (500MHz, DMSO-D6, 30 °C): δ 6.80
(ddd, 1H, J= 8.0 Hz, J= 2.5 Hz, J= 1.0 Hz, Ar-3-OH), 7.05–7.09 (m,
2H, Ar-3-OH), 7.24 (t, 1H, J= 8.0 Hz, Ar-3-OH), 7.43 (d, 1H,
J= 16.5 Hz, CH=), 7.51 (d, 1H, J= 16.5 Hz, CH=), 8.26 (d, 1H,
J= 8.5 Hz, Ar-2,4-NO2), 8.48 (ddd, 1H, J= 8.5 Hz, J= 2.5 Hz,
J= 0.5 Hz, Ar-2,4-NO2), 8.74 (d, 1H, J= 2.5 Hz, Ar-2,4-NO2), 9.56 (s,
1H, OH). 13C NMR (125MHz, DMSO-D6, 30 °C): δ 113.6, 116.7, 118.7,
120.2, 120.9, 127.1, 129.2, 129.9, 136.9, 137.5, 137.6, 145.8, 147.2,
157.7. FTIR (νmax/cm-1): 3429, 3094, 2356, 1627, 1594, 1580, 1515,
1344, 1290, 1254, 1211, 1168, 1153, 1125, 1091, 1064, 997, 978, 950,
922, 905, 876, 849, 833, 770, 755, 741, 727, 700, 678, 654, 605, 580.
HRMS (ESI): C14H10N2O5Na+, calcd. m/z 309.0487- found 309.0489.
4-hydroxy-2′,4′-dinitrostilbene (8), Yield 14 %, the product was
crystallized from a small amount of methanol. 1H NMR (500MHz,
DMSO-D6): δ 6.83 (d, 2H, J= 9.0 Hz, Ar-4-OH), 7.27 (d, 1H,
J= 16.0 Hz, CH=), 7.50–7.55 (m, 3H, Ar-4-OH and CH=), 8.21 (d,
1H, J= 9.0 Hz, Ar-2,4-NO2), 8.43 (dd, 1H, J= 9.0 Hz, J= 2.5 Hz, Ar-
2,4-NO2), 8.70 (d, 1H, J= 2.5 Hz, Ar-2,4-NO2), 9.94 (s, 1H, OH). 13C
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NMR (125MHz, DMSO-D6): δ 115.9, 117.2, 120.4, 126.9, 127.0, 128.5,
129.4, 137.9, 138.1, 145.1, 146.8, 159.1. FTIR (νmax/cm-1): 3462,
3097, 3071, 1624, 1612, 1591, 1578, 1513, 1339, 1320, 1278, 1267,
1235, 1209, 1196, 1173, 1148, 1128, 1109, 1064, 975, 962, 941, 914,
874, 860, 836, 831, 822, 792, 760, 739, 728, 713, 685, 651, 641. HRMS
(ESI): C14H10N2O5Na+, calcd. m/z 309.0487- found 309.0486.
3-hydroxy-4-methoxy-2′,4′-dinitrostilbene (9), Yield 60 %, product
was crystallized from ethanol. 1H NMR (500MHz, CDCl3): δ 3.81 (s,
3H, CH3O), 6.98 (d, 1H, J= 8.5 Hz, Ar-3-OH-4-OCH3), 7.08 (dd, 1H,
J= 8.5 Hz, J= 2.0 Hz, Ar-3-OH-4-OCH3), 7.12 (d, 1H, J= 2.0 Hz, Ar-
3-OH-4-OCH3), 7.27 (d, 1H, J= 16.0 Hz, CH=), 7.51 (d, 1H,
J= 16.0 Hz, CH=), 8.24 (d, 1H, J= 9.0 Hz, Ar-2,4-NO2), 8.44 (ddd,
1H, J= 9.0 Hz, J= 2.5 Hz, J= 0.5 Hz, Ar-2,4-NO2), 8.71 (d, 1H,
J= 2.5 Hz, Ar-2,4-NO2), 9.23 (s, 1 H). 13C NMR (125MHz, CDCl3): δ
55.6, 112.1, 113.3, 118.1, 120.4, 120.5, 127.0, 128.6, 128.7, 137.8,
137.9, 145.3, 146.8, 146.9, 149.4. FTIR (νmax/cm-1): 3471, 3093,
3019, 2992, 2946, 2851, 1625, 1616, 1595, 1577, 1522, 1509, 1495,
1455, 1438, 1339, 1323, 1299, 1287, 1275, 1260, 1222, 1207, 1182,
1159, 1147, 1134, 1123, 1063, 1022, 967, 923, 901, 876, 864, 841,
834, 828, 811, 759, 737, 728, 719, 677, 651. HRMS (ESI):
C15H12N2O6Na+, calcd. m/z 339.0593 -found 339.0594.
2.2. NMR measurements
All the spectra were recorded using a Varian VNMRS spectrometer
operating at 11.7 T magnetic ﬁeld. Measurements were performed for
ca. 1.0 M solutions of all the compounds in DMSO-d6 or CDCl3. The
residual signals of DMSO-d6 (2.54 ppm) and of CDCl3 (7.26 ppm) in 1H
NMR and of the DMSO-d6 signal (40.4 ppm) and of CDCl3 (77.0 ppm) in
13C NMR spectra were used as the chemical shift references. Spin
multiplicities are described as s (singlet), d(doublet), t (triplet), q
(quartet), m (multiplet), dd (double doublet). Coupling constants are
reported in Hertz. All the proton spectra were recorded using the
standard spectrometer software and parameters set: acquisition time
3 s, pulse angle 30°. The standard measurement parameter set for 13C
NMR spectra was: pulse width 7 μs (the 90° pulse width was 12.5 μs),
acquisition time 1 s, spectral width 200 ppm, 1000 scans of 32 K data
point were accumulated and after zero-ﬁlling to 64 K; and the FID
signals were subjected to Fourier transformation after applying a 1 Hz
line broadening. The 1H-13Cgs-HSQC and 1H-13Cgs-HMBC spectra were
also recorded using the standard Varian software.
2.3. Biological evaluation
2.3.1. Cell culturing
HeLa, U87, HEK293, Eufa cell lines were cultured in DMEMmedium
(Life Technology) supplemented with 10 % fetal bovine serum (Life
Technology) and 0.1 % antibiotics (penicillin, streptomycin, Life
Technology). Cells were grown in a humidiﬁed atmosphere of CO2/air
(5/95 %) at 37 °C.
2.3.2. Cytotoxicity assay
Exponentially growing cells were seeded onto a 96-well plate at the
density of 2× 103 cells/well, cultured for 18 h, and treated with new
derivatives at indicated concentrations (1–200 μM), or with DMSO as a
control, for 24 or 48 h. Alamar Blue (Invitrogen) was added accordingly
to the manufacturer protocol. After 4 h, light emission at 590 nm was
measured with excitation at 560 nm using a scanning multiwell spec-
trophotometer (DTX 880, Beckman Coulter). The experiment was car-
ried out at least three times with three replicates for each inhibitor
concentration. After background subtraction, inhibition rates (IC50)
were calculated as the concentration of the component inhibiting cell
growth by 50 %. All the calculations were performed using Origin 9.0
software.
2.3.3. Flow cytometry
The Annexin V-FITC apoptosis detection kit (BD Biosciences) was
used to detect apoptosis by ﬂow cytometry. Cells were seeded at 6-well
plates at a concentration of 5×105 cells/well, cultured for 18 h, and
tested agent was applied for indicated periods. Subsequently, cells were
washed with PBS, resuspended in binding buﬀer at a concentration of
2×106 cells/ml, and anti-Annexin V FITC-conjugated antibody and
propidium iodide were added to 100 μl aliquots. The mixtures were
incubated for 15min at room temperature, supplemented with a
binding buﬀer to 500 μl and processed by BD FACSCalibur (BD
Biosciences). Data were analyzed in Flowing Software version 2.5.1
(Flowing Software, http://www.uskonaskel.ﬁ/ﬂowingsoftware).
2.4. Computational aspects
The optimum ground-state geometry for compounds (4), (6) and (8)
was calculated using density functional theory (DFT) [40,41]. The
B3LYP functional and 6-311++g (2d,p) basis set and the continuum
model (PCM; Gaussian 03W) [35,36]was used in order to simulate the
eﬀects of the solvent -DMSO. All calculations were performed on a
server equipped with a 16 quad-core XEON (R) CPU E7310 processor
operating at 1.60 GHz. The operating system was Open SUSE 10.3 (see
Supplementary data).
2.4.1. Molecular docking simulations
The experimental crystal structure of tubulin (PDB entry: 1SA0) was
used in docking experiments [42,43]. Chains A, B, E as well as GTP,
GDP, magnesium ion and ligand were removed before docking from
receptor structure. CYS241, LEU248, LYS254, LEU255, VAL315,
ASN350, LYS352 and ILE378 were set as ﬂexible residues. The Gra-
phical User Interface (GUI), including python scripts for ligand and
receptor preparation, was part of AutoDock Tools 1.5.6. AutoDock suite
and AutoDocktools (ADT) are provided by the Scripps Research In-
stitute (http://autodock.scripps.edu/). The optimum ground-state geo-
metry of ligand compounds was calculated using the density functional
theory (DFT). In calculation, the B3LYP functional and 6-311++g
(2d,p) basis set was employed and the continuum model (PCM; Gaus-
sian 03W) [35,36] was used in order to simulate the eﬀects of the
solvent. The colchicine docking site was determined from the DAMA-
colchicine crystallized structure. The centres of the box were set
(X=39.82, Y=53.24, Z = -8.21) and its dimensions were set to
21× 21×21 Å. The exhaustiveness parameter was equal to 8. Docking
calculations were performed using AutoDock Vina software [44]. The
best-docked structure was chosen using the binding energy score given
by AutoDock Vina. All computations were performed on an Intel®
CoreTM i7-4702MQ 3.2 GHz processor running Ubuntu 18.04 Work-
station Linux distribution. PyMOL software (www.pymol.org/) was
used to analyze the docking results [45]. The Protein-Ligand Interaction
Proﬁler (PLIP) was used in order to predict protein-docked ligand in-
teractions [46].
3. Results and discussion
Here we report the synthesis and cytotoxic eﬀect of six stilbenes and
three oxepine derivatives against two cancerous – HeLa and U87, and
two normal – EUFA30 and HEK293 cell lines. We also performed mo-
lecular docking of these derivatives to tubulin (Fig. 3).
3.1. Chemistry
The routes synthetic are summarized in Scheme 1. Compounds (1),
(4), (7)-(10) were obtained in two synthetic steps starting from the
condensation of suitable aldehyde and 2,4-dinitrotoluene (Experi-
mental section and Supplementary material). For dibenzo[b,f]oxepines
the next step was the reaction between a derivative of 2,4-dini-
trostilbene and sodium azide. In the reactions arise corresponding nitro-
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dibenzo[b,f]oxepine (1) and (4). The product (1) was a substrate in the
reaction with paraformaldehyde in the presence of a Lewis acid as the
catalyst (BF3·OEt2) and with 4,4′-diethoxy-1,1′-biphenyl. This process
was successfully conducted, which enables the incorporation of aryl
groups, (product 3) to the dibenzo[b,f]oxepin framework [27]. Stil-
benes (5a) and (5) (6) was prepared according to modiﬁed literature
procedures [47,27]: titanium tetrachloride and suitable methoxy alde-
hyde. In the reaction of stilbene (5a) with Lewis BF3·OEt2 acid (the
catalyst of cyclization reaction), it was obtained cyclic stilbene - tetralin
(5) [25]. Compound (5a) and the ethyl ester of (2) were not tested
because they did not dissolve in DMSO.
3.2. Cytotoxic eﬀect of stilbenes and oxepines towards cultured normal and
cancer cells
In the present study, we evaluated the cytotoxic eﬃcacy of six
stilbenes and three oxepine derivatives on two cancerous – HeLa and
U87, and two normal – EUFA30 and HEK293 cell lines (concentrations
tested: 1–300 μM, Fig. 4, Table 1). Stilbene/oxepin-mediated growth
inhibition proceeded in a dose-dependent manner and the eﬀect was
stronger for HeLa than U87 cells and for Eufa than HEK293 cells.
Generally, stilbenes were more cytotoxic than oxepins, and most of
them were more toxic to cancerous than normal cells. Compounds with
the smallest IC50 value and the highest selectivity were three stilbene -
(6), (8), and (9), IC50 value for HeLa cells were 109.2, 35.6 and 112.9
μM comparing to 756.4, 162.2 and 504.4 μM for Eufa30 cells, respec-
tively. Oxepine (4) was the compound with the best biological activity,
but with no selectivity. Further tests were performed on stilbenes (6)
and (8), and oxepine (4).
To measure apoptosis induction, cells were treated with 100 μM for
24 and 48 h with 100 μM of (6), of (8) and of (4) (Fig. 5). The ex-
periment was performed on one normal (Eufa30), and one cancer
(HeLa) cell lines. The HeLa cells were more sensitive to stilbenes (6)
and (8), than Eufa30 cells. In Eufa30 cells, after 24 h of (6) treatment,
no signiﬁcant increase in apoptosis or/and necrosis was observed,
whereas HeLa cells showed a signiﬁcant increase in necrotic cells,
namely, from 17.2 % in untreated to 61.5 % in treated cells. After
treatment with (8), Eufa30 cells showed a signiﬁcant increase in early
apoptosis from 0.4% to 9.6% after 24 h, and from 0.7% to 18.2 % after
48 h of treatment. In HeLa cells, a signiﬁcant increase in necrotic cells
after 24 and 48 h of treatment from 17.2% to 31.4 % and from 20.2% to
64.6%, respectively, was observed. Interestingly, stilbenes (6) and (8
showed diﬀerent mechanism of action on normal and cancer cells –
after stilbene treatment most of the Eufa30 cells were in the early stages
of apoptosis, and HeLa cells in the necrosis phase. Oxepine (4) showed
the strongest cytotoxic eﬀect, however, with no selectivity of action
against cancer and normal cells: about 90 % of the Eufa and Hela cells
were observed to be in the late stage of apoptosis.
3.3. NMR spectra and computational analysis
In order to determine the structure of the reaction products oxepine
(1,3,4) and stilbene derivatives (5-10) in solution, 1H and 13C NMR
spectra of all of the products have been measured (Supporting in-
formation). The 1H and 13C NMR resonances were assigned unequi-
vocally, based on the combined information from 1D and 2D NMR
(gCOSY, gHSQC, and gHMBC) experiments. Coupling constants (1H-1H)
were measured directly from resolution-enhanced 1D spectra and
conﬁrmed, when necessary, by homo-decoupling. gHSQC and gHMBC
analysis allowed the assignment of the regiochemistry of the products.
The optimum structures of the best biological activity compounds (4),
(6) and (8) were calculated using the DFT B3LYP/6-311++G(2d, p)
method (and with polarizable continuum model-PCM, Gaussian 03W)
[35,36] (see supporting information). Optimized geometry of com-
pounds (4), (6) and (8) were used in molecular docking.
3.4. Molecular docking simulations to tubulin in colchicine binding site
The integration of computational and experimental investigations
has been of great value in the identiﬁcation and development of novel
promising compounds. Broadly used molecular docking methods ex-
plore the ligand conformations adopted within the binding sites of
Fig. 3. The structure of: 6-methoxy-3-nitrodibenzo[b,f]oxepine (1), [1,1′-biphenyl]-4,4′-diol (2), 3-((4,4′-diethoxy-[1,1′-biphenyl]-3-yl)methyl)-4-methoxy-7-ni-
trodibenzo[b,f]oxepine (3), 9-nitrobenzo[b]naphtho[1,2-f]oxepine (4), 7-methoxy-1,2,3-tris(4-methoxyphenyl)-1,2,3,4-tetrahydronaphthalene (5), (E)-4,4′-di-
methoxystilbene (5a), (E)-3,3′,4,4′,5,5′-hexamethoxystilbene (6), 3-hydroxy-2′,4′-dinitrostilbene (7), 4-hydroxy-2′,4′-dinitrostilbene (8), 3-hydroxy-4-methoxy-2′,4′-
dinitrostilbene (9) and 3-ethoxy-4-hydroxy-2′4′-dinitrostilbene (10).
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macromolecular targets. This approach also estimates the ligand-re-
ceptor binding free energy by evaluating critical phenomena involved
in the intermolecular recognition process. Therefore, in our tests, the
best active compounds (4), (6) and (8) to interact with tubulin (crystal
structure from PDB code: 1SA0) [38] has been analyzed by computer
molecular modeling. The molecular docking was performed by simu-
lation of compound compounds (4), (6) and (8) into the colchicine
binding site in tubulin (see supporting information). All docking runs
were applied using the Broyden- Fletcher-Goldfarb-Shanno (BFGS)
method of AutoDock Vina program [39]. The binding model of com-
pounds (4), (6) (8) and tubulin is depicted in Fig. 6.
In the binding mode, compounds (4), (6), (8) bind to the colchicine
binding site of tubulin via hydrophobic interactions and binding is
stabilized by a hydrogen bond. The hydroxyl group of (8) behaves as a
hydrogen bond acceptor, interacting with Lysβ254. The calculated
binding energies were used as parameters for the selection of the cluster
of docking posed to be evaluated (Fig. 6 a, b, c), in which the binding
mode of the lowest energy structure was located (selection of the cluster
in docking for the lowest energy structure of investigated molecule).
The selected structure of (4), (6), (8) had an estimated binding free
energy of -10.4, -7.0, -8.8 kcal/ mol respectively (binding free energy of
control compounds colchicine and CA-4 are -8.6 kcal/mol and
-7.62 kcal/mol, respectively [48]). The model was similar to the models
between colchicine, CA-4 and the colchicine binding site [49,50]. In the
(4) binding model, more details revealed that there were some key roles
of the interaction between (4) and tubulin (Fig. 6a). The compound (4)
was embedded in the hydrophobic pocket occupied by the A ring of
colchicine (van der Waals contact with Alaβ316, Lysβ254, Alaβ250,
and Leuβ248). The next compound (6) also interact with Leuβ248 and
Leuβ255. The product (8) aﬀects Leuβ248 and Lysβ254. These results
suggest that compound (4) could interact stronger and compounds (6)
and (8) less with tubulin, relative to colchicine and CA-4.
4. Conclusion
In summary, we have developed an easy and high-yielding synthesis
for compounds 5, 5a, 6, 8 and 9 (which are the derivatives of dibenzo
[b,f]oxepine or stilbene) from respectively substituted benzaldehydes
and 2,4-dinitrotoluene. Molecules 4, 7, 8 and 10 were obtained with
lower yields. The cytotoxic eﬀect of all obtained products to two can-
cerous (HeLa and U87), and two normal (EUFA30 and HEK293) cell
lines were measured. Notably, the most active compounds were one
dibenzo[b,f]oxepine (4) and two stilbene derivatives, (6) and (8).
Analysis of the binding model of the most active compounds (4), (6)
and (8) with tubulin allowed to discover several interactions with the
protein residues in the colchicine binding site. The compound (4) could
interact stronger with tubulin, relative to colchicine, however, with no
selectivity of action against cancer and normal cells. Inversely, com-
pounds (6) and (8) interact weaker with tubulin, relative to colchicine
but they act more selectively towards cancerous versus normal cell
lines. Presented results are valuable premise to look for more powerful
anticancer drugs based on the mechanism of inhibition of tubulin
polymerization.
Scheme 1. Synthesis of dibenzo[b,f]oxepine (1, 3, 4) and stilbene derivatives (1a, 4a, 5a, 5, 6, 7, 8, 9, 10).
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Fig. 4. The cytotoxic eﬀect of indicated stilbene and dibenzo[b,f]oxepin derivatives on normal EUFA30 and HEK293 cells and cancerous HeLa and U87 cells based on
AlamarBlue assay after 24 and 48 h of treatment. Non-linear ﬁtting with a logistic dose-response model was employed and IC50 values calculated if possible (see
Table 1).
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Table 1
IC50 (μM) of tested dibenzo[b,f]oxepine (1,3,4) and stilbene derivatives (5-10) based on the survival of EUFA30, HEK293, HeLa, and U87 cells after 24 and 48 h of
treatment. “*” - The predicted IC50 (above the maximum concentration tested – 300 μM), “N/A” –the IC50 could not be calculated.
Compound Eufa30 HEK293 HeLa U87
24 48 24 48 24 48 24 48
oxepines (1) N/A N/A 733.8* N/A N/A N/A N/A N/A
(2) N/A 368.1* N/A 592.6* 319.6* 238.0 506.7* N/A
(3) N/A N/A N/A 346.4* N/A N/A N/A N/A
(4) 21.0 20.2 129.1 290.8 44.2 79.4 28.0 75.3
stilbenes (5) N/A N/A N/A N/A N/A N/A N/A N/A
(6) 756.4* 819.3* N/A N/A 109.2 503.1* N/A N/A
(7) 398.0* 562.3* 268.7 267.8 184.7 241.2 583.1* N/A
(8) 162.2 132.2 172.2 130.9 35.6 117.1 175.9 194.0
(9) 504.4* 553.6* N/A 644.0* 112.9 N/A N/A N/A
(10) N/A 324.4* N/A N/A 298.8 N/A 168.5 600.4*
Fig. 5. Flow cytometry analysis of Eufa30 and HeLa cells stained with Annexin-FITC (A) and propidium iodide (PI) of (4), (6) and (8).
Fig. 6. 3D model of the interaction between compounds: a) (4), b) (6) c) (8) and the colchicine binding site of α and β tubulin (crystal structure from PDB code:
1SA0).
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